Genetic Technology Alert. Plazomicin Antibiotic for Treatment of CRE; Development of Recombinant Human Growth Factor Hormone; Enzyme Inhibition Therapy to Treat Obesity and Related Diseases

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles plazomicin antibiotic for treatment of CRE, development of recombinant human growth factor hormone, and an enzyme inhibition therapy to treat obesity and related diseases.

Table of Contents

Genetic Technology Alert. Plazomicin Antibiotic for Treatment of CRE; Development of Recombinant Human Growth Factor Hormone; Enzyme Inhibition Therapy to Treat Obesity and Related DiseasesIn This Issue1. PLAZOMICIN ANTIBIOTIC FOR TREATMENT OF CRE2. DEVELOPMENT OF RECOMBINANT HUMAN GROWTH FACTOR HORMONE3. ENZYME INHIBITION THERAPY TO TREAT OBESITY AND RELATED DISEASES4. RECENT PATENTS IN ANTIBIOTICS




Keyword1

Keyword2

Keyword3

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.